Petmed Express Inc

Petmed Express Inc(PETS)股票分析

$1.220

+0.041 (+3.39%)收盘时

Loading chart…
最高
1.265
开盘
1.170
成交量加权均价
1.22
成交量
272.24K
市值
86.14M
最低
1.170
成交额
331.68K
企业价值/息税折旧摊销前利润(TTM)
-0.93

PetMed Express, Inc., doing business as PetMeds, is a direct-to-consumer pet pharmacy. The Company is an online provider of prescription and non-prescription medications, food, supplements, and supplies and has veterinary and pet insurance service partnerships for dogs, cats, and horses. It markets and sells directly to consumers through their Websites, toll-free numbers, and employer benefit partnerships. Its product line contains over 15,000 SKUs of pet medications, health products, foods, and supplies. The Company offers various pet supplies, including beds, crates, stairs and other pet supplies. Its products include Prescription Medications (Rx), Non-Prescription Medications (OTC) and supplies, Pet Foods, Private Label and Holistic Wellness Services. Rx includes heartworm and flea and ticks preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes.

AI 分析 of Petmed Express Inc (PETS)

持有

PetMed Express Inc is not a good buy right now. The current price is $1.22, and the stock has a negative year-to-date change of -63.03%. Additionally, the RSI is at 47.78, indicating that the stock is neither overbought nor oversold, which suggests a lack of strong momentum. The recent acquisition proposal at $3.00 per share indicates potential value, but the company's deteriorating financials, including a net income loss of $6.14 million in the last quarter, pose significant risks.

分析师评级(5)

买入
2 买入
2 持有
1 卖出
当前: 1.22
最低
—
平均
—
最高
—

Morgan Stanley

2026-09-25

目标价

—

减持

Morgan Stanley

2025-04-17

目标价

$3.2

卖出

Lake Street

2024-08-07

目标价

$3.5

持有

Morgan Stanley

2024-06-12

目标价

$3.5

卖出

Lake Street

2024-06-12

目标价

$7

强烈买入

估值指标

Petmed Express Inc(PETS)当前预期市盈率为 16.69,5 年平均预期市盈率为 -10.13。

预期市盈率

合理
5 年均值 P/E
-10.13
当前P/E
16.69
高估
97.15
低估
-117.42

预期 EV/EBITDA

低估
5 年均值 EV/EBITDA
7.78
当前EV/EBITDA
-0.93
高估
14.50
低估
1.07

预期市销率

合理
5 年均值 P/S
0.76
当前P/S
0.17
高估
1.35
低估
0.16

Alphio AI 对 PETS 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%PETS

$4.12

情景价格

基

基准

基准 · 50%PETS

$3.76

情景价格

悲

悲观

悲观 · 25%PETS

$3.08

情景价格

持有 PETS 的大户

O

Oaktop Capital Management II, L.P.

+ 持有PETS

-13.50%

3个月收益率

事件时间线

2026-09-21 (ET)

09:00:00

PetMed Express Appoints Tamar Elkeles as Independent Director

2026-09-17 (ET)

09:00:00

PetMed Express Appoints Jeff Willard as CEO

2026-09-14 (ET)

16:30:00

PetMed Express Appoints Andrew Parry as CTO

2026-07-23 (ET)

08:30:00

PetMed Express Enters $37M Sale-Leaseback Agreement with Investor

2026-06-30 (ET)

10:00:00

PetMed Express Receives $3.00 Acquisition Proposal from SilverCape

资讯

PETS 常见问题 —— 由 Alphio AI 解答

PetMed Express, Inc., doing business as PetMeds, is a direct-to-consumer pet pharmacy. The Company is an online provider of prescription and non-prescription medications, food, supplements, and supplies and has veterinary and pet insurance service partnerships for dogs, cats, and horses. It markets and sells directly to consumers through their Websites, toll-free numbers, and employer benefit partnerships. Its product line contains over 15,000 SKUs of pet medications, health products, foods, and supplies. The Company offers various pet supplies, including beds, crates, stairs and other pet supplies. Its products include Prescription Medications (Rx), Non-Prescription Medications (OTC) and supplies, Pet Foods, Private Label and Holistic Wellness Services. Rx includes heartworm and flea and ticks preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes. It operates in the Consumer Non-Cyclicals sector (RETAIL-DRUG STORES AND PROPRIETARY STORES industry).

PetMed Express Inc is not a good buy right now. The current price is $1.22, and the stock has a negative year-to-date change of -63.03%. Additionally, the RSI is at 47.78, indicating that the stock is neither overbought nor oversold, which suggests a lack of strong momentum. The recent acquisition proposal at $3.00 per share indicates potential value, but the company's deteriorating financials, including a net income loss of $6.14 million in the last quarter, pose significant risks.

5 analysts cover PETS: 2 rate it Buy, 2 Hold and 1 Sell.

暂无帖子

注册或登录后参与讨论

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易